HGS Invests In Oncology As Phase III Drugs Near Submission
This article was originally published in The Pink Sheet Daily
Executive Summary
Human Genome Sciences targets 2010 for Albuferon and LymphoStat-B launches.
You may also be interested in...
HGS: LymphoStat-B For Lupus Not Like Failed Rituxan
Analysts cautiously optimistic the antibody candidate will succeed.
HGS: LymphoStat-B For Lupus Not Like Failed Rituxan
Analysts cautiously optimistic the antibody candidate will succeed.
HGS First Quarter Results Fair; Bigger News Ahead
Despite others’ setbacks, firm maintains optimism for Phase III lupus drug.